Putting the brakes on drug-resistant HIV

Sep 17, 2010

(PhysOrg.com) -- HIV-1 protease inhibitors were added as a component of highly active antiretroviral therapy (HAART) in the mid-1990s, and have played a key role in that treatment regimen ever since. However, the emergence of multidrug-resistant HIV strains requires the discovery and design of conceptually new therapeutics for the treatment of patients infected with multidrug-resistant HIV strains.

In addressing this issue, the research group of Arun K. Ghosh at Purdue University developed stereochemically defined, fused tetrahydrofuran (THF) ligands based on the X-ray crystal structures of HIV--ligand complexes. The results of this project, carried out with collaborators at Georgia State University, Kumamoto University in Japan, and the National Cancer Institute, are reported in the journal ChemMedChem.

The fused THF ligands contain five contiguous chiral centers, and were synthesized in optically active form by enzymatic resolution, radical cyclization, and stereoselective reduction as key steps. The resulting HIV-1 protease inhibitors are designed to interact specifically with protein backbone atoms by hydrogen bond formation and by filling the hydrophobic active site pocket. One compound in particular, GRL-0519A, shows remarkable protease inhibition and .

Moreover, this compound is extremely potent against various multidrug-resistant HIV-1 variants, with IC50 values ranging from 0.6 to 4.3 nanomolar. In fact, GRL-0519A is at least 10-fold better than darunavir, an FDA-approved inhibitor that emerged from previous research by Ghosh's group.

Explore further: Chemists modify antibiotic to vanquish resistant bacteria

More information: Arun K. Ghosh, Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors, ChemMedChem, dx.doi.org/10.1002/cmdc.201000318

add to favorites email to friend print save as pdf

Related Stories

Metal-containing compounds show promise as HIV weapon

Oct 31, 2005

A molecule consisting of two "cages" of metallic atoms bound to carbon has shown great promise in preliminary tests of becoming a new weapon in the anti-HIV arsenal, researchers at UT Southwestern Medical Center report. The ...

Anti-HIV drugs reduce the cause of some forms of vision loss

May 23, 2008

A potential new therapeutic use for anti-HIV drugs known as protease inhibitors has been suggested by a team of researchers from Harvard Medical School, Boston, and Inserm U848, France, as a result of their work in a mouse ...

Researchers urge integrating TB into HIV care

Jul 22, 2008

In resource-limited settings where tuberculosis is a major cause of mortality among HIV patients and where a multidrug-resistant TB epidemic is emerging, researchers are pressing for approaches to integrate TB prevention ...

Resistant HIV quickly hides in infants' cells

Apr 30, 2007

New evidence shows that drug-resistant virus passed from mother-to-child can quickly establish itself in infants’ CD4+ T cells where it can hide for years, likely limiting their options for future treatment. The study is ...

Recommended for you

A refined approach to proteins at low resolution

40 minutes ago

Membrane proteins and large protein complexes are notoriously difficult to study with X-ray crystallography, not least because they are often very difficult, if not impossible, to crystallize, but also because ...

Base-pairing protects DNA from UV damage

3 hours ago

Ludwig Maximilian University of Munich researchers have discovered a further function of the base-pairing that holds the two strands of the DNA double helix together: it plays a crucial role in protecting ...

User comments : 0